basal like breast cancer

Release time ：Dec-24,2024

Basal-like breast cancer represents a distinct subtype of breast cancer, often characterized by a poor prognosis, responsiveness to chemotherapy, but a propensity for high recurrence rates.

Treatment for basal-like breast cancer predominantly hinges on a multimodal therapeutic approach, encompassing surgery, radiotherapy, and chemotherapy. Given the absence of effective targeted therapies for this breast cancer subtype, chemotherapy emerges as the primary treatment. Common chemotherapeutic agents include anthracyclines and taxanes, which are adept at eliminating cancer cells but may also engender a spectrum of adverse effects, such as nausea, vomiting, alopecia, and myelosuppression. Furthermore, for patients with early-stage basal-like breast cancer, breast-conserving surgery combined with radiotherapy constitutes a viable treatment option, yielding survival rates comparable to those achieved with total mastectomy.

For individuals afflicted with basal-like breast cancer, timely medical intervention and adherence to standardized treatment protocols are of paramount importance. Concurrently, patients should focus on psychological adjustment, uphold healthy lifestyle practices, and actively collaborate with their healthcare providers' treatment plans to bolster therapeutic outcomes and enhance their quality of life. Regarding medication, patients must strictly adhere to their physician's instructions, refraining from altering dosages or discontinuing medication without guidance, to ensure optimal treatment efficacy.